Assessment of Gut Absorption of Experimental Medication BMS-986165 in Healthy Males

Completed · Phase 1

Conditions studied: Psoriasis

In brief

The purpose of this study is to evaluate sites of gut absorption of BMS-986165 in males

Key facts

Study ID

NCT03873415

Run by

Bristol-Myers Squibb

People needed

9

Starts

2019-01-25

Expected to finish

2019-05-01

Last updated by the study team

2019-11-26

Who can join

Age: 18 and older, up to 45. Sex: male. Healthy volunteers: accepted.

You may qualify if…

• Body mass index of 18.0 to 32.0 kg/m2, inclusive, and weight ≥ 50 kg, at screening
• Estimated glomerular filtration rate (eGFR) > 80 mL/min/1.732 calculated with the Chronic Kidney Disease Epidemiology Collaboration formula

You may not qualify if…

• Any significant acute or chronic medical illness
• Current or recent (within 3 months of study drug administration) disease of the gut that, in the opinion of the Investigator or Medical Monitor, could impact upon the absorption of study drug
• Acute diarrhea, or constipation within 3 weeks prior to randomization
• Any major surgery within 4 weeks of randomization
• Other protocol defined inclusion/exclusion criteria could apply

Where it is running

• Scintipharma — Lexington, Kentucky, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.